We are boosting cell rejuvenation to treat currently incurable neurodegenerative and rare genetic diseases
Autophagy (from the Ancient Greek: ”self-eating”) is the cell’s main method for recycling damaged components and this process declines with age. There is compelling evidence that boosting autophagy leads to increased healthspan and lifespan, while impaired autophagy drives many serious diseases.
We are enhancing healthspan, by building an unbiased data-driven drug discovery engine
We’re letting our proprietary data guide us in new and unexpected directions to find better ways to restore autophagy. This approach allows us to uncover novel biology and gives us fundamental insights into how the cell controls this process. It’s led us very quickly to first in class, disease modifying programs which have exciting therapeutic activity.
Samsara Therapeutics adds eminent neurologist Professor Dame Pamela Shaw to its scientific advisory board to help accelerate ALS/MND treatment development
Samsara Therapeutics, the autophagy biotech company, has appointed eminent neurologist and world-leading researcher in Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND) Professor Dame Pamela Shaw to its scientific advisory board.
Samsara Therapeutics announced today that it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to further its research into a promising Parkinson’s disease drug.
Samsara Therapeutics unveils promising autophagy drug candidate, offering new hope for people with Parkinson’s and motor neurone disease
Samsara Therapeutics is first in the race to find a viable, potent autophagy inducing drug, with the potential to give us longer and healthier lives.
We caught up with Senior Scientists Gabriela Vilema Enríquez and Matthew Williamson on their work within the neuroscience team at Samsara.